Table 4.
The relationship between the modified Glasgow Prognostic Score and clinicopathological factors in patients undergoing potentially curative resection for gastric cancer
| Clinicopathological factors | mGPS = 0 | mGPS = 1 | mGPS = 2 | p value |
|---|---|---|---|---|
| Age (years) | ||||
| < 65 | 78 (33.8%) | 11 (35.5%) | 10 (34.5%) | 0.885 |
| 65–75 | 94 (40.7%) | 13 (41.9%) | 14 (48.3%) | |
| > 75 years | 59 (25.5%) | 7 (22.6%) | 5 (17.2%) | |
| Sex | ||||
| Female | 78 (33.8%) | 9 (29.0%) | 10 (34.5%) | 0.863 |
| Male | 153 (66.2%) | 22 (71.0%) | 19 (65.5%) | |
| Tumor site | ||||
| Proximal | 76 (32.9%) | 8 (25.8%) | 11 (37.9%) | 0.697 |
| Body | 54 (23.4%) | 7 (22.6%) | 4 (13.8%) | |
| Distal | 101 (43.7%) | 16 (51.6%) | 14 (48.3%) | |
| T stage | ||||
| 1 | 63 (27.3%) | 3 (9.7%) | 1 (3.4%) | 0.001 |
| 2 | 20 (8.7%) | 4 (12.9%) | 3 (10.3%) | |
| 3 | 81 (35.1%) | 14 (45.2%) | 10 (34.5%) | |
| 4 | 67 (29.0%) | 10 (32.3%) | 15 (51.7%) | |
| N stage | ||||
| 0 | 107 (46.3%) | 12 (38.7%) | 12 (41.4%) | 0.471 |
| 1 | 48 (20.8%) | 8 (25.8%) | 7 (24.3%) | |
| 2 | 45 (19.5%) | 4 (12.9%) | 3 (10.3%) | |
| 3 | 31 (13.4%) | 7 (22.6%) | 7 (24.1) | |
| Tumor stage | ||||
| I | 73 (31.6%) | 4 (12.9%) | 2 (6.9%) | 0.013 |
| II | 66 (28.6%) | 14 (45.2%) | 12 (41.4%) | |
| III | 92 (39.8%) | 13 (41.9%) | 15 (51.7%) | |
| Differentiation | ||||
| Well/moderate | 127 (55.0%) | 12 (38.7%) | 11 (37.9%) | 0.030 |
| Poor | 104 (45.0%) | 19 (61.3%) | 18 (62.1%) | |
| Vascular invasion | ||||
| No | 135 (58.4%) | 21 (67.7%) | 12 (41.4%) | 0.105 |
| Yes | 96 (41.6%) | 10 (32.3%) | 17 (58.6%) | |
| Lymph node ratio | ||||
| 0 | 107 (46.3%) | 12 (38.7%) | 12 (41.4%) | 0.196 |
| 0.01–0.24 | 57 (24.7%) | 10 (32.3%) | 8 (27.6%) | |
| 0.25–0.49 | 49 (21.2%) | 2 (6.5%) | 3 (10.3%) | |
| ≥ 50 | 18 (7.8%) | 7 (22.6%) | 6 (20.7%) | |
| Lymph node sample | ||||
| ≥ 15 | 107 (46.3%) | 11 (35.5%) | 16 (55.2%) | 0.306 |
| < 15 | 124 (53.7%) | 20 (64.5%) | 13 (44.8%) | |
| R status | ||||
| 0 | 199 (86.1%) | 26 (83.9%) | 21 (72.4%) | 0.068 |
| 1 | 32 (13.9%) | 5 (16.1%) | 8 (27.6%) | |
| Adjuvant chemotherapy | ||||
| No | 117 (76.6%) | 27 (87.1%) | 26 (89.7%) | 0.052 |
| Yes | 54 (23.4%) | 4 (12.9%) | 3 (10.3%) | |
| Neoadjuvant therapy | ||||
| No | 176 (76.2%) | 27 (87.1%) | 28 (96.6%) | 0.020 |
| Yes | 55 (23.8%) | 4 (12.9%) | 1 (3.4%) | |
| White cell count | ||||
| Low | 172 (74.5%) | 23 (74.2%) | 10 (34.5%) | 0.002 |
| Normal | 41 (17.7%) | 7 (22.6%) | 15 (51.7%) | |
| High | 18 (7.8%) | 1 (3.2%) | 4 (13.8%) | |
| Neutrophil count | ||||
| Low | 216 (92.6%) | 31 (100.0%) | 19 (65.5%) | < 0.001 |
| High | 17 (7.4%) | 0 (0.0%) | 10 (34.5%) | |
| Lymphocyte count | ||||
| Low | 17 (7.4%) | 5 (16.1%) | 5 (17.2%) | 0.160 |
| Normal | 201 (87.0%) | 26 (83.9%) | 23 (79.3%) | |
| High | 13 (5.6%) | 0 (0.0%) | 1 (3.4%) | |
| Platelet count | ||||
| Low | 210 (90.9%) | 28 (90.3%) | 22 (75.9%) | 0.046 |
| High | 21 (9.1%) | 3 (9.7%) | 7 (24.1%) | |
| Neutrophil-lymphocyte ratio | ||||
| Low | 219 (94.8%) | 27 (87.1%) | 15 (51.7%) | < 0.001 |
| High | 12 (5.2%) | 4 (12.9%) | 14 (48.3%) | |
| Neutrophil-platelet score | ||||
| Low | 197 (85.3%) | 28 (90.3%) | 14 (48.3%) | < 0.001 |
| Intermediate | 30 (13.0%) | 3 (9.3%) | 12 (41.4%) | |
| High | 4 (1.7%) | 0 (0.0%) | 3 (10.0%) | |
| Platelet-lymphocyte ratio | ||||
| Low | 128 (55.4%) | 7 (22.6%) | 8 (27.6%) | < 0.001 |
| High | 103 (44.6%) | 24 (77.4%) | 21 (72.4%) | |